<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232592</url>
  </required_header>
  <id_info>
    <org_study_id>Chinese ASZQ-005</org_study_id>
    <nct_id>NCT04232592</nct_id>
  </id_info>
  <brief_title>Clinical Safety Study of Human Embryonic Stem Cell Derived Mesenchymal Cells in the Treatment of Moderate and Severe Intrauterine Adhesions</brief_title>
  <official_title>Clinical Safety Study of Human Embryonic Stem Cell Derived Mesenchymal Cells in the Treatment of Moderate and Severe Intrauterine Adhesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qi Zhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the clinical safety of intrauterine injection of human embryonic stem cell derived&#xD;
      mesenchymal cells in the treatment of moderate and severe intrauterine adhesion, and to&#xD;
      preliminarily explore its clinical effectiveness in promoting endometrial regeneration and&#xD;
      repair.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, a single-center, controlled, open-label design was used for a dose escalation&#xD;
      study.To observe the clinical safety of intrauterine injection of human embryonic stem cell&#xD;
      derived mesenchymal cells in the treatment of moderate and severe intrauterine adhesion, and&#xD;
      to preliminarily explore its clinical effectiveness in promoting endometrial regeneration and&#xD;
      repair.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of different Adverse Events of transplantation of mesenchymal cells from human embryonic stem cells</measure>
    <time_frame>Within 48 weeks after surgery</time_frame>
    <description>Adverse events (AE), severe adverse events (SAE), and treatment-related adverse events (TEAE) occurred within 48 weeks after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normal recovery rate of endometrial thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Normal recovery rate of endometrial thickness at 1 and 2 months after surgery will be measured (effective rate = endometrium &gt; 6mm after surgery/all participants ×100%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence rate of intrauterine adhesions</measure>
    <time_frame>12 months</time_frame>
    <description>Recurrence rate of intrauterine adhesions (defined as patients with recurrence of intrauterine adhesions reviewed by hysteroscopy at 1 month/total patients ×100%) will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine adhesions score</measure>
    <time_frame>12 months</time_frame>
    <description>Intrauterine adhesions score will be measured according to the American Fertility Society in 1988 diagnostic criteria for intrauterine adhesions.The scores range from 1 to 12. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The endometrial biopsies for CD31</measure>
    <time_frame>12 months</time_frame>
    <description>Immunohistochemical results of CD31 during the two endometrial biopsies will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual volume change</measure>
    <time_frame>12 months</time_frame>
    <description>Menstrual volume change will be assessed according to menstrual blood loss chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical pregnancy rate, abortion rate, live birth rate, and sustained pregnancy rate (defined as live pregnancy over 12 weeks) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The endometrial biopsies for estrogen</measure>
    <time_frame>12 months</time_frame>
    <description>Estrogen receptor levels during the two endometrial biopsies will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The endometrial biopsies for Ki67</measure>
    <time_frame>12 months</time_frame>
    <description>Ki67 expression levels during the two endometrial biopsies will be measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Intrauterine Adhesion</condition>
  <arm_group>
    <arm_group_label>Stem cell preparation solution injection group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The solution of stem cells preparation will be injected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injected stem cell group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The stem cells will injected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inject a solution of stem cell preparation</intervention_name>
    <description>The control group was injected with a solution of stem cell preparation</description>
    <arm_group_label>Stem cell preparation solution injection group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inject stem cells</intervention_name>
    <description>Three dose groups were designed: low dose group, medium dose group and high dose group.</description>
    <arm_group_label>Injected stem cell group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  18 ≤ age ≤38, female;&#xD;
&#xD;
          -  According to the 1988 American Fertility Society (AFS) diagnostic criteria, patients&#xD;
             with uterine adhesions diagnosed with full civil capacity and with a score of ≥5 were&#xD;
             enrolled in the study;&#xD;
&#xD;
          -  The patient had one or more of the following clinical symptoms: reduced menstruation&#xD;
             or amenorrhea, periodic abdominal pain, secondary infertility, recurrent abortion,&#xD;
             premature delivery and other adverse pregnancy outcomes;&#xD;
&#xD;
          -  The uterus was smaller than 8 weeks gestation and the uterine cavity depth was less&#xD;
             than 12 cm;&#xD;
&#xD;
          -  The second to fifth day of menstruation FSH &lt;10mIU/mL, AMH &gt;1.2ng/mL, AFC&gt;6;&#xD;
&#xD;
          -  Understand and sign informed consent voluntarily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with acute pelvic inflammation or endometriosis;&#xD;
&#xD;
          -  Having or having a history of malignancy;&#xD;
&#xD;
          -  Thrombus, lupus erythematosus and other hormone use contraindications; Allergic to&#xD;
             albumin products;&#xD;
&#xD;
          -  Patients with uterine malformation, adenomyosis, submucosal uterine fibroids,and&#xD;
             uterine fibroids of any site &gt;5cm;&#xD;
&#xD;
          -  Patients who were using anticoagulants or who had not recovered normal platelet&#xD;
             function 10 days after discontinuation of antiplatelet drugs;&#xD;
&#xD;
          -  Previous history of abnormal coagulation function or abnormality before cell&#xD;
             transplantation;&#xD;
&#xD;
          -  Always has a history of abnormal bleeding (such as abnormal bleeding during tooth&#xD;
             extraction), or their immediate family members have hemorrhagic disease,such as&#xD;
             hemophilia, bleeding symptoms (e.g., hematemesis, black, serious or recurrent nasal&#xD;
             bleeding, coughing up blood, obvious hematuria, gastrointestinal bleeding, or&#xD;
             intracranial hemorrhage), or suspected of vascular malformation such as aneurysm by&#xD;
             researchers determine influence cell implant operation;&#xD;
&#xD;
          -  Alcohol or drug addiction;&#xD;
&#xD;
          -  Participated in other interventional clinical trials within 90 days before the&#xD;
             informed consent was signed or before the cell transplantation;&#xD;
&#xD;
          -  Had used glucocorticoids or immunosuppressive drugs within 12 weeks before signing the&#xD;
             informed consent;&#xD;
&#xD;
          -  Had used antipsychotic drugs, such as antidepressants and anti-manic drugs, within 12&#xD;
             weeks before signing the informed consent;&#xD;
&#xD;
          -  Severe heart failure within 24 weeks before the informed consent;&#xD;
&#xD;
          -  Glomerular filtration rate (eGFR) &lt;90ml/min;&#xD;
&#xD;
          -  ALT&gt;3 times normal upper limit;&#xD;
&#xD;
          -  Concomitant with other serious systemic diseases, such as pulmonary heart disease,&#xD;
             severe chronic obstructive pulmonary disease (COPD), etc;&#xD;
&#xD;
          -  Patients with severe clinical infection should receive antibiotics within 1 week&#xD;
             before signing the informed consent;&#xD;
&#xD;
          -  Active infectious diseases, including but not limited to positive human&#xD;
             immunodeficiency virus and syphilis antibody;&#xD;
&#xD;
          -  The researchers considered poor compliance;&#xD;
&#xD;
          -  Other conditions not suitable for participation in this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qi Zhou, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of zoology, Chinese Academy of Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liu Wang, Doctor</last_name>
    <phone>+86-01064807858</phone>
    <email>wangliu@ioz.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Hao, Doctor</last_name>
    <phone>+86-01062558737</phone>
    <email>haojie@ioz.ac.cn</email>
  </overall_contact_backup>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 27, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Qi Zhou</investigator_full_name>
    <investigator_title>Director of Institute of zoology, chinese academy of sciences, and vice president of medical school， University of chinese academy of sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

